{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T09:47:41Z","timestamp":1779184061130,"version":"3.51.4"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,29]],"date-time":"2017-05-29T00:00:00Z","timestamp":1496016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"The Odd Fellow Foundation"},{"name":"European Community's Seventh Framework Programme","award":["602699"],"award-info":[{"award-number":["602699"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Immunology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.molimm.2017.05.021","type":"journal-article","created":{"date-parts":[[2017,6,11]],"date-time":"2017-06-11T03:15:45Z","timestamp":1497150945000},"page":"111-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Eculizumab-C5 complexes express a C5a neoepitope in vivo: Consequences for interpretation of patient complement analyses"],"prefix":"10.1016","volume":"89","author":[{"given":"Per H.","family":"Nilsson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anub Mathew","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grethe","family":"Bergseth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Gustavsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena B.","family":"Volokhina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lambertus P.","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Barratt-Due","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom E.","family":"Mollnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.molimm.2017.05.021_bib0005","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.molimm.2013.05.221","article-title":"An international serum standard for application in assays to detect human complement activation products","volume":"56","author":"Bergseth","year":"2013","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.molimm.2017.05.021_bib0010","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00228-016-2027-z","article-title":"Off-label use of the expensive orphan drug eculizumab in France 2009\u20132013 and the impact of literature: focus on the transplantation field","volume":"72","author":"Castaneda-Sanabria","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.molimm.2017.05.021_bib0015","first-page":"83","article-title":"Freeze-thaw activation of the complement attack phase: II. Comparison of convertase generated C\u201356 with C\u201356 generated by freezing and thawing","volume":"284","author":"Dessauer","year":"1984","journal-title":"Acta Pathol. Microbiol. Immunol. Scand. Suppl."},{"key":"10.1016\/j.molimm.2017.05.021_bib0020","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1046\/j.1365-2249.2003.02213.x","article-title":"Pre-neutralization of C5a-mediated effects by the monoclonal antibody 137-26 reacting with the C5a moiety of native C5 without preventing C5 cleavage","volume":"133","author":"Fung","year":"2003","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.molimm.2017.05.021_bib0025","doi-asserted-by":"crossref","first-page":"892","DOI":"10.4049\/jimmunol.131.2.892","article-title":"Activation of the fifth and sixth components of the human complement system: c6-dependent cleavage of C5 in acid and the formation of a bimolecular lytic complex, C5b, 6a","volume":"131","author":"Hammer","year":"1983","journal-title":"J. Immunol."},{"key":"10.1016\/j.molimm.2017.05.021_bib0030","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.addr.2011.05.010","article-title":"Advances in assay of complement function and activation","volume":"63","author":"Harboe","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.molimm.2017.05.021_bib0035","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1182\/blood-2016-08-732800","article-title":"Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation","volume":"129","author":"Harder","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.molimm.2017.05.021_bib0040","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molimm.2017.05.021_bib0045","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.bbmt.2015.10.002","article-title":"Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"22","author":"Jodele","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.molimm.2017.05.021_bib0050","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nsmb.3196","article-title":"Structural basis for therapeutic inhibition of complement C5","volume":"23","author":"Jore","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.molimm.2017.05.021_bib0055","doi-asserted-by":"crossref","first-page":"15861","DOI":"10.1073\/pnas.0903613106","article-title":"Human genetic deficiencies reveal the roles of complement in the inflammatory network: lessons from nature","volume":"106","author":"Lappegard","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molimm.2017.05.021_bib0060","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molimm.2017.05.021_bib0065","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1016\/j.molimm.2007.06.150","article-title":"Complement analysis in the 21st century","volume":"44","author":"Mollnes","year":"2007","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.molimm.2017.05.021_bib0070","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molimm.2017.05.021_bib0075","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000463173","article-title":"A sensitive enzyme immunoassay for the quantitation of human C5a\/C5a(desArg) anaphylatoxin using a monoclonal antibody with specificity for a neoepitope","volume":"8","author":"Oppermann","year":"1991","journal-title":"Complement. Inflamm."},{"key":"10.1016\/j.molimm.2017.05.021_bib0080","doi-asserted-by":"crossref","first-page":"337","DOI":"10.4049\/jimmunol.1600280","article-title":"Structural basis for eculizumab-mediated inhibition of the complement terminal pathway","volume":"197","author":"Schatz-Jakobsen","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.molimm.2017.05.021_bib0085","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/0161-5890(89)90057-6","article-title":"Non-enzymic activation of the fifth component of human complement, by oxygen radicals Some properties of the activation product, C5b-like C5","volume":"26","author":"Vogt","year":"1989","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.molimm.2017.05.021_bib0090","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/blood-2015-03-637645","article-title":"Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivo","volume":"126","author":"Volokhina","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.molimm.2017.05.021_bib0095","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/cei.12890","article-title":"Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders","volume":"187","author":"Wehling","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.molimm.2017.05.021_bib0100","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0165-2478(87)90103-9","article-title":"Generation of an activated form of human C5 (C5b-like C5) by oxygen radicals","volume":"14","author":"von Zabern","year":"1987","journal-title":"Immunol. Lett."}],"container-title":["Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589017301554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589017301554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T18:20:13Z","timestamp":1719253213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161589017301554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":20,"alternative-id":["S0161589017301554"],"URL":"https:\/\/doi.org\/10.1016\/j.molimm.2017.05.021","relation":{},"ISSN":["0161-5890"],"issn-type":[{"value":"0161-5890","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eculizumab-C5 complexes express a C5a neoepitope in vivo: Consequences for interpretation of patient complement analyses","name":"articletitle","label":"Article Title"},{"value":"Molecular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molimm.2017.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}